Lexaria Bioscience Corp. (LEXX) has a consensus analyst rating of Buy, based on 2 analysts covering the stock. Of those, 2 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for LEXX is $1.50, representing a +47.1% upside from the current price of $1.02. Price targets range from a low of $1.50 to a high of $1.50.
